Improving bladder cancer treatment by targeting DNA repair deficiencies
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-10918108
This study is looking at how certain gene changes in people with muscle-invasive bladder cancer might help doctors decide the best treatment options, like whether to remove the bladder or use a combination of chemotherapy and radiation, to improve outcomes for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10918108 on ClinicalTrials.gov |
What this research studies
This research investigates how deficiencies in the nucleotide excision repair (NER) pathway, specifically mutations in the ERCC2 gene, affect treatment outcomes for patients with muscle-invasive bladder cancer (MIBC). The study aims to determine if these mutations can serve as molecular biomarkers to guide treatment decisions between bladder removal and bladder-sparing chemoradiotherapy. By analyzing patient responses to cisplatin-based chemotherapy and clinical chemoradiotherapy regimens, the research seeks to enhance personalized treatment approaches for MIBC patients. The methodology includes examining tumor samples and treatment responses to identify patterns linked to ERCC2 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle-invasive bladder cancer, particularly those with ERCC2 mutations.
Not a fit: Patients with non-muscle-invasive bladder cancer or those without ERCC2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with muscle-invasive bladder cancer.
How similar studies have performed: Previous research has shown that targeting DNA repair deficiencies can improve treatment responses in other cancers, suggesting potential success for this approach in bladder cancer.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOUW, KENT W — DANA-FARBER CANCER INST
- Study coordinator: MOUW, KENT W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer